3,7-Dimethyl-N-(3,5-dimethyl-4-hydroxyphenyl)-2,6-octadienamide | 130211-75-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3,7-Dimethyl-N-(3,5-dimethyl-4-hydroxyphenyl)-2,6-octadienamide
• 英文别名: (2E)-N-(4-hydroxy-3,5-dimethylphenyl)-3,7-dimethylocta-2,6-dienamide
• CAS: 130211-75-5
• 化学式: C₁₈H₂₅NO₂
• 分子量: 287.4
• InChiKey: DHHFBYCCRPXVDQ-UKTHLTGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 4-Aminophenol derivatives and processes for preparing the same
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP0374048A1

  公开（公告）日：1990-06-20

  There are disclosed a 4-aminophenol derivative of the formula: (wherein R¹ and R² each represent a lower alkyl group, Y represents a single bonding arm, a lower alkylene group or a lower alkenylene group, R³ represents a thienyl group or pyrrolyl group which may be also substituted with a lower alkyl group; benzothienyl group, indolyl group; or a phenyl group which is substituted with 1 to 2 groups selected from a lower alkoxy group and a lower alkanoyloxy group; or Y-R³ represents integrally an alkyl group with 6 to 9 carbon atoms; or a hydrocarbon group with 5 to 14 carbon atoms having 2 or 3 double bonds) or a pharmacologically acceptable salt thereof, and pro­cesses for preparing the same.

  公开了一种4-氨基苯酚衍生物，其式如下 (其中R¹和R²各代表一个低级烷基，Y代表一个单键臂、一个低级亚烷基或一个低级亚烯基，R³代表一个噻吩基或吡咯基，它们也可被一个低级烷基取代；苯并噻吩基、吲哚基；或被 1 至 2 个选自低级烷氧基和低级烷酰氧基的基团取代的苯基；或 Y-R³ 整体代表 6 至 9 个碳原子的烷基；或具有 2 或 3 个双键的 5 至 14 个碳原子的烃基）或其药理学上可接受的盐，以及制备这些盐的工艺。
• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.
• Method and composition for treating inflammatory disorders
  申请人：Pereswetoff-Morath Lena

  公开号：US20090220583A1

  公开（公告）日：2009-09-03

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• Method and Composition for Treating Inflammatory Disorders
  申请人：Meda AB

  公开号：US20160166508A1

  公开（公告）日：2016-06-16

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• US5047555A
  申请人：——

  公开号：US5047555A

  公开（公告）日：1991-09-10